Translating all the information from the genomics revolution into verifiable drug targets has proven to be no easy task. Now, in an effort to bend the curve toward R&D success, GlaxoSmithKline is teaming up with external experts, putting up money and brainpower to launch a collaborative research effort.
After collaborating with the University of Michigan-spinout NanoBio over the past three years, Merck has signed off on a new licensing pact for the biotech's nanoemulsion adjuvant technology.
AstraZeneca has launched a website with hopes of opening up its R&D efforts to would-be collaborators, posting its compound bank and soliciting new ideas from academia, industry and government.
George Scangos, CEO of biotech powerhouse Biogen Idec, and David Page, director of MIT's Whitehead Institute for Biomedical Research, have made a $5.3 million handshake, the Boston Globe reports, as the two institutions plan to collaborate on early-phase development.
Oncology biotech Tesaro will use a cancer test developed by Myriad Genetics to look for tumor types that may respond to PARP inhibitors like niraparib, a Phase III candidate in ovarian cancer and breast cancer, in-licensed from Merck in 2012.
With the departure of Astellas and now Biogen Idec, Aveo Oncology is fresh out of collaborators, sending the struggling biotech back to the partnering table as it looks to advance an early-stage cancer drug.
The Japanese Global Health Innovative Technology Fund said it will invest nearly $15 million to advance new drugs for neglected tropical diseases as well as fund the development of a vaccine candidate for tuberculosis.
The French Big Pharma is paying SK Chemicals $23 million up front, after which both companies will invest in the project.
What does $190 million in R&D spending get you? In the case of Alder Biopharmaceuticals, it got a blockbuster $1.35 billion development deal with Bristol-Myers Squibb and an in-house migraine drug headed into a Phase IIb study. It also takes the biotech to the threshold of an IPO it detailed today, which is designed to raise $115 million to fund operations through 2015.
Diagnostics maker Corgenix revealed that it might offer itself up as an M&A target, which is one of several options the small-but-growing outfit is exploring in an effort to boost its shareholder value in 2014.